SHANGHAI, Mar 16, 2020 – (ACN Newswire) – Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. For the year ended December 31, 2019, the Company incurred approximately RMB468.5 million in total expenses, of which approximately RMB 321.9 million was research and development expenses. As of December 31, 2019, the Company's cash position was approximately RMB 1,105.6 million.
Hua Medicine will continue to execute on its strategic goal of becoming a global diabetes care and management company, and is devoted to the development, registration and launch of dorzagliatin (HMS5552) in China and around the world. Hua Medicine achieved many milestones in 2019. The core scientific concept for dorzagliatin as a first-in-class drug was further validated, and the dorzagliatin-driven portfolio of diabetes therapies reflected in our pipeline continued to expand and advance. The Phase III monotherapy trial (HMM0301) for dorzagliatin (HMS5552) achieved its primary efficacy endpoint. The study results indicated that dorzagliatin was well tolerated during the 24-week study period, exhibited very low incidences of hypoglycemia and had a good safety profile. Meanwhile, two Phase I clinical trials with dorzagliatin (HMM0110 and HMM0111) also demonstrated satisfactory results. The results of HMM0110 demonstrated that dorzagliatin has the potential to be used in Type 2 diabetes (T2D) patients with moderate, severe and end stage chronic kidney disease (i.e., stages 3-5 of CKD); several top-selling oral anti-diabetes drugs must undergo dose adjustment (e.g., metformin and sitagliptin) when used for such T2D patients, or simply can't be used at all for such patients (e.g., select SGLT-2 inhibitors). The results of HMM0111 confirmed the clinical advantages and potential synergies of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor), one of the best-selling oral anti-diabetic drugs globally.
The diagnosis rate of Type 2 diabetes is relatively low in China. Accordingly, there is a huge population of non-diagnosed and drug-naive T2D patients in China, which provides a big market opportunity for dorzagliatin. Current diabetes therapies still cannot effectively restore the healthy body's ability to control blood glucose level autonomously, nor modify or stop the progression of diabetes into more advanced stages of the disease, leading to the development of diabetes-associated complications. In contrast, the results of pre-clinical and clinical studies (both completed and those currently under development) demonstrate that dorzagliatin has the potential to treat the underlying cause of Type 2 diabetes by fixing the impaired glucose sensor in all T2D patients and thereby restoring glucose homeostasis. Research data to date suggests that, as a cornerstone therapy, dorzagliatin possesses the potential of controlling the development of diabetes and preventing or delaying the occurrence of complications, either via monotherapy or through combination with currently available diabetes therapies.
"We will carry on implementing our developmental strategy, which consists of expanding in three dimensions: new products, global markets and new disease indications. By deploying dorzagliatin as a cornerstone therapy, we will establish an innovative, sharing and win-win scientific platform that focuses on the remodeling of glucose homeostasis, and eventually realize the personalized medicine of diabetes globally," said Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine.
Clinical trial Highlights
– Achieved 24-week primary efficacy endpoint in a double blinded placebo controlled Phase III trial in drug naive Type 2 diabetes (T2D) patients in China (HMM0301), with very low hypoglycemia incidents and good safety profiles. As of March 2, 2020, the last patient out, 52-week (plus one-week follow-up) patient visit for HMM0301 was completed.
– Completed enrollment in a metformin add-on Phase III registration trial (HMM0302). As of February 16, 2020, the 24-week patient visit for HMM0302 was completed.
– Completed HMM0110, which demonstrated desirable pharmacokinetics profile in patients with end stage chronic kidney disease, indicating the potential use of dorzagliatin among T2D patients with moderate, severe and end stage chronic kidney disease (i.e. stages 3-5 of CKD).
– Completed HMM0111, which investigated the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of dorzagliatin either alone or in combination with sitagliptin (a DPP-4 inhibitor) in T2D patients, and demonstrated combination and synergy potential between the two drugs.
– Granted a formulation patent for dorzagliatin in China.
– Filed six patent applications covering the IPR of fixed dose combination of dorzagliatin with six classes of oral anti-diabetic drugs.
– Fully validated the cGMP (current Good Manufacturing Practice) commercial manufacturing processes for active pharmaceutical ingredient (API) and drug product to support the launch of dorzagliatin in China.
Operational highlights
– Initiated a formal collaboration relating to the central role of glucokinase in controlling glucose homeostasis with Dr. Franz Matschinsky,professor of Biochemistry and Biophysics, Institute for Diabetes, Obesity and Metabolism Perelman School of Medicine, Philadelphia and the recipient of the 1995 Banting Medal for Scientific Achievement and the 2020 Rolf Luft Award.
– Presented AI-based machine learning results at the American Diabetes Association's 79th Scientific Sessions, providing a non-biased methodology to sub-classify T2D patients.
– Announced that global operation headquarters and research and development center were established in Shanghai's ZhangJiang Science City.
– Former U.S. FDA Officer Dr. Fuxing Tang joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development.
Financial Highlights
– Cash position was approximately RMB1,105.6 million as of December 31, 2019.
– Loss before tax decreased by approximately RMB3,178.7 million or approximately 88.2% to approximately RMB425.3 million.
Future Pipeline Outlook
– The Company plans to announce top-line 52-week Phase III trial result for the monotherapy trial (HMM0301) by no later than third quarter 2020.
– The Company plans to announce top-line 24-week Phase III result for the combination with metformin trial (HMM0302) by no later than third quarter 2020, and top-line 52-week result by year end 2020.
– The Company plans to partner with either China-based or international pharmaceutical companies to make dorzagliatin and related products, as brand new therapies, available to patients, in both China and regions outside of China.
– HMM0109 is a Phase I trial studying the pharmacokinetics profile for hepatic impaired patients in China.
– HMM0112 is a dorzagliatin combination with empagliflozin (a SGLT-2 inhibitor) Phase I trial in T2D patients in the United States. The Company announced the first patient was dosed in April 2019 and expect to complete and announce results by first half 2020.
– In order to continue expansion of dorzagliatin's indications for the treatment of T2D, the Company is investigating the combination of dorzagliatin with various approved classes of oral anti-diabetic medicines and expand the dorzagliatin-driven portfolio to address patients' personal needs.
About Dorzagliatin
Dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in people with type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of people with type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Tag: BioTech
ASGE Releases Recommendations for Endoscopy Units in the Era of COVID-19
DOWNERS GROVE, IL / ACCESSWIRE, Mar 14, 2020 – (ACN Newswire) – The American Society for Gastrointestinal Endoscopy (ASGE) has released an important article in its signature publication, the Gastrointestinal Endoscopy (GIE) journal. The article, titled "Coronavirus (COVID-19) Outbreak: What the Department of Endoscopy Should Know", is written by ASGE member, Dr Alessandro Repici and his colleagues who have first-hand experience and are still in the middle of the COVID-19 crisis in Italy.
 |
Endoscopy is a place where patients and physicians have very close distance and physicians are exposed to splashes, mucus or saliva during procedures especially upper gastrointestinal (GI) endoscopy. Moreover oral-fecal transmission has been postulated as a potential route for COVID-19 transmission. Endoscopy is also a place with significant concentration of people (staff, patients, caregivers, relatives, etc.) This is why establishing detailed and strict rules is of paramount importance to protect both personnel and patients.
Even though health care personnel working in endoscopy units are not directly involved in the diagnostic and therapeutic evaluation of COVID-19 positive patients, endoscopy should still be regarded as a risky procedure. This risk of exposure and subsequent infection of endoscopy personnel is, in fact, substantial in cases of patients with respiratory disease that can be spread via an airborne route.
The risk of exposure of endoscopy personnel is also not limited to upper endoscopy procedures, considering the recent detection of SARS-CoV in biopsy specimens and stools, suggesting a possible fecal-oral transmission. This could be even more relevant given that the virus transmission can occur during the incubation period in asymptomatic patients.
Establishing infection prevention measures and guidelines within an endoscopy department is essential for creating a high-quality and extremely safe environment to protect both patients and personnel. In this new era of the COVID-19 outbreak, it is imperative that these measures be implemented and maintained to avoid further spread of the disease.
"We recognize that ASGE members and their patients globally need to be diligent in maintaining individual health while minimizing disruption to day-to-day endoscopic practices and overall regional economies," said John Vargo, MD, FASGE, President of ASGE. "It is a challenging time for the whole world, and endoscopists and physicians have the additional responsibility of protecting both patients and their own well-being."
Read the GIE article. https://pr.report/IWK3r6dG
ASGE would like to express its appreciation to the authors for sharing their first-hand experience with other medical professionals around the world. They are currently in the middle of providing critical patient care at their medical institution, but felt it was important to also share their knowledge to minimize the global impact of this outbreak.
About the American Society for Gastrointestinal Endoscopy
Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with more than 15,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area.
For more information, contact:
Andrea Lee
Director of Marketing and Communications
American Society for Gastrointestinal Endoscopy
3300 Woodcreek Dr.
Downers Grove, IL 60515
USA
alee@asge.org
+1-630-5705603
SOURCE: American Society for Gastrointestinal Endoscopy
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Agilex Biolabs Announces 30% Labs Expansion and Offers Virtual Lab Tours During COVID-19 Outbreak
Adelaide, AUS, Mar 13, 2020 – (ACN Newswire) – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.
 |
As the only FDA-inspected lab of its type in the region, Agilex is located in Adelaide, South Australia, in a science and biotech specialist hub.
The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine / biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)
Agilex Biolabs CEO Jason Valentine said they will now be offering virtual tours of the lab for customers who have travel restrictions during the current Covid-19 outbreak.
CEO Jason Valentine said:
"Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma / biotechs from US, Europe and APAC.
"By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.
"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."
Learn more:
– Watch the Agilex Biolabs video: https://youtu.be/3lyodiqqM_k
– Download the New Services data sheet: https://tinyurl.com/AgilexBiolabs
About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980's, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 8302 8777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.
Media Contact:
Team@DMGPR.Com
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
TOT BIOPHARM Garners “Listing Award of Technological Company” and “Innovative Technological Research and Development Award”
HONG KONG, Mar 9, 2020 – (ACN Newswire) – On 6 March 2020, a morale-enhancing conference themed "Working Towards a World-class High-tech ePark & a New Summit for Reform and Opening-up in the New Era" was held at Suzhou Industrial Park, during which leading companies and top professionals in the Park were recognised for their achievements. At the event, TOT BIOPHARM International Company Limited has garnered the 2019 "Listing Award of Technological Company" and the "Innovative Technological Research and Development Award".
 |
Listed on the Stock Exchange of Hong Kong
Since its inception in Suzhou in July 2010, TOT BIOPHARM has its roots in the Park and continues to create innovations. It has focused on the development and commercialisation of innovative oncology drugs and treatments, with the aim of building a leading brand of oncology treatments trusted by patients and their families as well as medical professionals in China. In November 2019, the Company was listed on the Main Board of Hong Kong Stock Exchange under stock code: 1875.HK.
Innovative Technologies
TOT BIOPHARM has been increasing investments over the years. It has established an antibody drug production base with a designed production capacity of 16,000L. It has also focused on technological innovation and product development, and, to date, it has created various anti-tumour drug series and genres. Six drug candidates have entered key clinical trials or more advanced stages, thus forming a comprehensive high quality drug product chain.
The Company has also developed Perfusion-Batch Hybrid Technology ("PB-Hybrid Technology"), being the first to apply this technology to commercial production in China and completed production and testing and verification of various products and batches, thus creating a mature technology for itself. The technology has disrupted the traditional process of large-scale monoclonal antibody cell expansion. Capacity can be expanded from 25L to 2000L directly, and eliminate the 10L, 50L, 200L and 500L increments, thereby simplifying the process, optimising product quality, shortening the production cycle and reducing capital expenditures, providing remarkable competitive advantages in production.
TOT BIOPHARM has devoted several years of efforts to the development of Antibody Drugs Conjugates (ADC) technology. Recently the Group has completed the R&D, pilot production and release of Phase I clinical research data of its ADC drug TAA013. It has also completed the R&D and production of several next-generation ADC drugs for its strategic partners. TOT BIOPHARM's ADC drug production plant is currently under construction, and is to become one of the very few GMP-compliant ADC commercial production plants in China, hence laying a foundation for the Company to develop in the ADC area and to seize the first-mover opportunities in the market.
Open Co-operation Pursuit of Breakthroughs
TOT BIOPHARM has developed the layout of the entire industrial chain and established a comprehensive and integrated industrial chain platform comprising R&D, clinical trials, production and commercialization capabilities. It has actively opened its cooperation platforms in order to explore innovative drug development projects while also introducing more opportunities for innovation as it has vigorously pursued breakthroughs through international cooperation.
This accolade is recognition and acknowledgement of TOT BIOPHARM's development in recent years. In the future, TOT BIOPHARM will adhere to its business philosophy of striking a balance between humans and technology, continue to step up innovation efforts and forge continued success, with the aim of making further contributions to the treatment of disease as well as the business and economic development of Suzhou Industrial Park.
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
TOT BIOPHARM Garners “Listing Award of Technological Company” and “Innovative Technological Research and Development Award”
HONG KONG, Mar 9, 2020 – (ACN Newswire) – On 6 March 2020, a morale-enhancing conference themed "Working Towards a World-class High-tech ePark & a New Summit for Reform and Opening-up in the New Era" was held at Suzhou Industrial Park, during which leading companies and top professinals in the Park were recognised for their achievements. At the event, TOT BIOPHARM International Company Limited has garnered the 2019 "Listing Award of Technological Company" and the "Innovative Technological Research and Development Award".
|
Listed on the Stock Exchange of Hong Kong
Since its inception in Suzhou in July 2010, TOT BIOPHARM has its roots in the Park and continues to create innovations. It has focused on the development and commercialisation of innovative oncology drugs and treatmees, with the aim of building a leading brand of oncology treatments trusted by patients and their families as well as medical professionals in China. In November 2019, the Company was listed on the Main Board of Hong Kong Stock Exchange under stock code: 1875.HK.
Innovative Technologies
TOT BIOPHARM has been increasing investments over the years. It has established an antibody drug production base with a designed production capacity of 16,000L. It has also focused on technological innovation and product development, and, to date, it has created various anti-tumour drug series and genres. Six drug candidates have entered key clinical trials or more advanced stages, thus forming a comprehensive high quality drug product chain.
The Company has also developed Perfusion-BatchHybrid Technology ("PB-Hybrid Technology"), being the first to apply this technology to commercial production in China and completed production and testing and verification of various products and batches, thus creating a mature technology for itself. The technology has disrupted the traditional process of large-scale monoclonal antibody cell expansion. Capacity can be expanded from 25L to 2000L directly, and eliminate the 10L, 50L, 200L and 500L increments, thereby simplifying the process, optimising product quality, shortening the production cycle and reducing capital expenditures, providing remarkable competitive advantages in production.
TOT BIOPHARM has devoted several years of efforts to the development of Antibody Drugs Conjugates (ADC) technology. Recently the Group has completed the R&D, pilot production and release of Phase I clinical research data of its ADC drug TAA013. It has also completed the R&D and production of several next-generation ADC drugs for its strategic partners. TOT BIOPHARM's ADC drug production plant is currently under construction, and is to become one of the very few GMP-compliant ADC commercial production plants in China, hence laying a foundation for the Company to develop in the ADC area and to seize the first-mover opportunities in the market.
Open Co-operation Pursuit of Breakthroughs
TOT BIOPHARM has developed the layout of the entire industrial chain and established a comprehensive and integrated industrial chain platform comprising R&D, clinical trials, production and commercialization capabilities. It has actively opened its cooperation platforms in order to explore innovative drug development projects while also introducing more opportunities for innovation as it has vigorously pursued breakthroughs through international cooperation.
This accolade is recognition and acknowledgement of TOT BIOPHARM's development in recent years. In the future, TOT BIOPHARM will adhere to its business philosophy of striking a balance between humans and technology, continue to step up innovation efforts and forge continued success, with the aim of making further contributions to the treatment of disease as well as the business and economic development of Suzhou Industrial Park.
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Novotech Wins CRO Contract for Komipharm Coronavirus Covid-19 Clinical Trial in South Korea
SEOUL, KOREA, Mar 6, 2020 – (ACN Newswire) – Asia-Pacific's largest specialist biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus – Covid-19. Komipharm is seeking to expand the use of Panaphix to cover the treatment of Covid-19 through this trial.
 |
Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines. The overproduction of immune cells and their signalling molecules leads to severe inflammatory disease such as pneumonia in some individuals.
Novotech CEO Dr Moller said Novotech was well positioned to partner with Komipharm on this important trial of a drug which is having a particularly strong impact in Asia Pacific. Novotech has offices in eleven locations throughout Asia Pacific, with experienced local leadership, the ability to engage with regulators, strong relationships with key opinion leaders, and sites in the region will allow it to accelerate this trial.
Novotech undertakes a large number of infectious diseases trials and has particularly strong relationships in this area. Novotech recently won the Australian-Korean Business Awards 2020 – Award for Excellence, in the category Biotech and Health.
Over the last 12 months Novotech has signed several formal partnerships with key hospitals in Korea, including Seoul National University, Asan Medical Center, Yonsei University Severance Hospital, and Ulsan University Hospital, to facilitate the project management of clinical trials and accelerate biotech drug development.
About Novotech
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). Novotech has been instrumental in the success of hundreds of Phase I – IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets.
Novotech also has worldwide reach through the company's network of strategic partners. https://novotech-cro.com/welcome. For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0
Media Contact:
Susan Fitzpatrick-Napier
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
AIM ImmunoTech joins with ChinaGoAbroad for an Ampligen China Entry against COVID-19
OCALA, FL / ACCESSWIRE, Feb 27, 2020 – (ACN Newswire) – AIM ImmunoTech (NYSE American: AIM, or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions.
CGA is a member-based online information platform and offline advisory firm serving to facilitate two-way international transactions relating to the PRC in close collaboration with the China Overseas Development Association (CODA), which had up until recently reported to the PRC National Development and Reform Commission (NDRC), which in turn reports to the State Council (China's cabinet). CGA is already involved in China's ongoing efforts to halt the growing COVID-19 epidemic and, among other engagements, has been assigned to assist with the international purchase by Sinopharm Group – a Chinese state pharmaceutical company – of technology, masks, gowns and gloves.
"AIM is working aggressively to advance the introduction of Ampligen into China, in order to provide the Chinese people with a potential first line of defense against the deadly COVID-19 virus. AIM and CGA have taken this first step to facilitate discussions with the Chinese government for Ampligen's entry into China as a targeted prophylactic/early-onset therapy," said AIM CEO Thomas K. Equels. "Ampligen achieved a 100% survival rate, as compared to 100% mortality in the untreated control animals, in SARS animal experiments after the outbreak in 2003. In these experiments, Ampligen was administered to mice prior to and shortly after infection. The Company believes that Ampligen may provide similarly effective prophylaxis against COVID-19, as both coronaviruses are extremely similar in key regulatory RNA sequences essential for coronaviral replication."
Ampligen has a well-developed safety profile based on approximately 100,000 IV doses administered to humans and is ready to deploy for clinical trials in China if trials are approved by the PRC authorities and if Ampligen is authorized for export under the FDA regulations governing the export of investigational drugs for use in a sudden and immediate national emergency. (See: "Ampligen as an Antiviral," safety slides 7-15, at https://aimimmuno.com/events-presentations/).
ChinaGoAbroad CEO Jesse T H Chang states: "Ampligen has the potential to be a groundbreaking life-saving protective therapy. This drug may be useful for doctors, nurses, healthcare professionals, first responders and people exposed to the virus. Without better protection, infected professionals in our medical teams may continue to become martyrs on the frontlines of the battle against this highly contagious virus. If Ampligen works in the clinic against COVID-19 the same way it worked in the SARS experiments, a protective drug such as Ampligen – unlike a mask and gloves – would provide immunological protection from the inside. For those inadvertently exposed to the virus, it may provide hope against infection or development of the disease. Such a protective therapy would also become an important public health tool against exposed people spreading the disease. We are excited and indeed honored to work with AIM ImmunoTech on this endeavor so important to the Chinese people."
In addition, you can find AIM's most recent stockholder update detailing Ampligen's potential in the epidemic here: https://aimimmuno.irpass.com/AIM-ImmunoTech-Issues-Stockholder-Update-on-the-Potential-Role-of-Ampligen-for-Use-Against-the-Wuhan-Coronavirus-Epidemic
About AIM ImmunoTech Inc
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen(R) or Rintamod(R)) and the FDA-approved drug Alferon N Injection(R). Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen(R) may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen(R) include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of the Wuhan Coronavirus in humans and no assurance can be given that it will be the case. The presentation and stockholders' letter referenced in this press release refer to a number of studies. No assurance can be given that future studies will not result in findings that are different from those reported in the referenced studies. This press release related to potential activity in China. Operating in foreign countries such as China carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential operations in China will not be adversely affected by these risks. With regard to the Company's activities with Ampligen generally, no assurance can be given as to whether current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Captiva Verde Land Corp – Corporate Update
Vancouver, BC, Feb 27, 2020 – (ACN Newswire) – Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the "Company" or "Captiva"), is pleased to announce the following updates for each of its business segments.
Mexico Pharmaceutical License
Captiva has started construction on its new manufacturing plant in Mexico to supply a wide range of psychoactive, heath and wellness, and narcotic medicines pursuant to our comprehensive pharmaceutical license to sell and distribute over 300 different types of psychoactive (psilocybin) and non-psychoactive (CBD) products. The plant will be finished in June and ready to produce in October of this year for positive accretive cash flow. Further, we have an arrangement to sell all of our products to the Union of Health Care Workers plus the larger group within the Union Federation, as a buying club of 1.2 Million members. Our products will be exceptional quality but priced for the Mexico market in the price range affordable in Mexico at a special discounted price for the benefit of the Union members and their families. This is a long term and sustainable strategy.
Solargram Farms
As stated in our previous news releases, one of the few remaining value propositions in the Cannabis business is to blow up the current status quo of high priced indoor cultivation with extremely low cost high quality outdoor grow. Last year, four (4) public companies produced only 3% of the legal Cannabis supply in Canada with outdoor grow operations. Their respective public disclosures list their total cost to produce at between 10 and 24 cents per gram vs $1.00 to $13.00 per gram for indoor grow, not including their destructively high G&A costs. Solargram was built to supply compassionate Cannabis at retail values well below that of the grey market, which grey market stubbornly controls 75% of the market share. The Solargram operations are almost complete and ready to commence licensed operations in early May with a very large ultra-low cost harvest ready for sale in October of this year.
Miss Envy
Miss Envy is an award winning health and wellness organization with the biggest selection of organic products in the market. Captiva has the world-wide rights outside of Canada. Captiva is currently developing the Miss Envy product line in Mexico to coordinate with the opening of our Mexican facility in June of this year. Miss Envy provides another one of the remaining value added propositions left in the industry, which is a world recognized brand with a huge following. Every time any other LP in the US or Canada sells a Cannabis product, they sell at a loss according to their public disclosures. This is not sustainable. Miss Envy offers a sustainable and profitable solution to the compassionate needs of the industry.
Meanwhile, Captiva is in the process of tweaking Miss Envy's product lines to better appeal to Asian consumers and exploring opportunities to procure substantial sales from the Asian community with Miss Envy, where the products and themes are very well received. Updates will be released as they become available.
Sage Ranch, California
Captiva owns 50% of the sustainable and affordable one-thousand (1,000) housing unit Sage Ranch subdivision in Southern California. The project will have its final California Environmental Impact Report issued on March 4th for the 45 day public review period and then approval in front of the Planning Commission and City Counsel in June of this year. Upon approvals and completion of a 30 day appeal period, construction will commence at the annualized rate of 150 to 250 homes per year.
Summary
Captiva Verde is a highly efficient, nimble, extremely low overhead, high impact and sustainable socially responsible investment company with a multitude of high value projects that will all succeed due to a very loyal shareholder base and an execution oriented, sharply focused and dedicated management team.
On Behalf of the Board of Directors
"Jeffrey Ciachurski"
For further information, please contact:
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca
Cautionary Note Regarding Forward Looking Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52846
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Oxford Medical Case shows Chiropractics can ease Dizziness and Neck Pain
HONG KONG, Feb 26, 2020 – (ACN Newswire) – Just 4 weeks of chiropractic adjustment stimulating proprioception helps people deal with physical pain and annoying dizziness, according to a new case report at Oxford Medical Case Reports.
 |
Neck muscles have numerous interactions with balance and visual centers. Neck problems can alter orientation in space and cause a disturbance of equilibrium. Cervicogenic dizziness is the dizziness associated neck pain and cervical disorders.
A 24-year-old office worker suffered from intermittent neck pain and dizziness for 2 years. She sought help at New York Medical Group and experienced dizziness by moving her head in different motion. All her blood tests, X-rays and MRI could not confirm her symptoms and medication only provided partial relief.
"Cervicogenic dizziness is a seemingly simple complaint for many working adults, but it can be a controversial diagnosis because there are no specific tests for doctors to use," says corresponding author Eric Chun-Pu Chu, chairman of Chiropractic Doctors Association of Hong Kong and author of the study.
The sensory inputs from the neck play an important role in head-eye coordination and postural processes. For example, fish do not have necks and their head and trunk move as one unit in one direction without dizziness. But human has a highly developed sensory system to receive signals and move our trunk. Neck proprioception provides the necessary information about head movements relative to the trunk.
Determining the cause of dizziness is crucial to tailoring the most appropriate treatment protocol. Ruling out neurovascular etiologies is equally important before starting the manual therapy to prevent any untoward events in dizziness.
Chiropractic adjustment has been shown to have benefits in treating many conditions such as headaches and numbness. But Chu and colleagues wanted to know whether a patient with cervicogenic dizziness might benefit from correction of neck posture.
Researchers tested the patient with cervical adjustment and thermal ultrasound therapy, with emphasis on restoring mobility to stiff joints and relieving muscle tightness. Restoration of the cervical curvature was demonstrable on cervical radiographs in the 7th month.
The effect of chiropractic adjustment and ultrasound therapy was effective enough, they found, that both pain and dizziness resolved after 4 weeks of treatments. Researchers found significant relationship between cervical pain and lordosis angle of < 20 degrees. After 18 months, the patient remained free of drugs and symptoms.
The stimulation of cervical proprioceptors and normalization of the afferent input were the result of manual therapy, the author noted.
"The resolution of neck pain or dizziness suggests there may be clinical benefits to chiropractic care in cervicogenic dizziness," Chu says.
Source: Chiropractic Doctors Association of Hong Kong
Study: doi.org/10.1093/omcr/omz115
Dr Eric Chun-Pu Chu
Chairman@cda.org.hk
Chiropractic Doctors Association of Hong Kong
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
HONG KONG, Feb 24, 2020 – (ACN Newswire) – Aptorum Group Limited ("Aptorum Group"), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms. The supplement is made with the bioactive ingredient extracted Chinese yam powder containing "DOI", which is Aptorum Group's non-hormonal approach intended to meet certain growing consumer nutritional trends and concerns. It is estimated that 1.2 billion women worldwide will be menopausal or postmenopausal by the year 20301. The global woman's health supplement market for menopausal symptoms is projected to reach over USD$50bn by 2025 with a CAGR rate of 16.4% (2016-2025)2. Initially, the supplement will be commercialized and sold in Hong Kong; the Company is seeking regulatory clearance to market the product in other major jurisdictions.
As part of the commercialization, Aptorum Group, through its wholly-owned subsidiary Nativus Life Sciences Limited, entered into a regional distribution agreement with Multipak Limited, a Hong Kong based group that operates household brands, including the Luk Yu tea bag and other health related products.
Through Multipak, Aptorum Group will be able to increase the accessibility of the product to a large consumer base regionally. The production of Aptorum Group's dioscorea opposita bioactive nutraceutical tablets has commenced production in Canada and will soon be marketed under the brand name NativusWellTM.
Nativus's NativusWellTM tablets are natural, non-hormonal supplements containing DOI. The yam powder with DOI utilizes a non-hormonal approach that is intended to boost the general wellness of women undergoing menopause. Third party scientific studies indicate that DOI, the naturally occurring bioactive ingredient in Chinese yam, appears to stimulate estradiol biosynthesis, induce estradiol and progesterone secretion and increase bone density, thereby potentially counteracting the progression of osteoporosis3, one of the common symptoms associated with menopause4.
For further general presentation, please visit: http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16
For further technical presentation, please visit: http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 World Health Technical Report Series. Research on the Menopause in the 1990's. Geneva, Switzerland: World Health Organization; 1996.
2 https://www.grandviewresearch.com/press-release/global-isoflavones-market
3 https://www.ke.hku.hk/story/innovation/the-magic-of-chinese-yam-for-treatment-of-menopausal-syndrome; see also, Scientific Reports, 5-10179.
4 https://www.everydayhealth.com/menopause/osteoporosis-and-menopause.aspx
Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
theacnnewswire.news.blog 